Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Asoprisnil · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | EXPERIMENTAL | - |
| Arm 4 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Asoprisnil (BAY86-5294) | DRUG | 5mg/day |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Patients with treatment-resistant menorrhagia scheduled for hysterectomy. Exclusion Criteria: * Organic causes of menorrhagia * Current hormone treatment
Asoprisnil is an investigational small molecule being studied for the treatment of menorrhagia, a condition characterized by heavy menstrual bleeding. It is being developed by Bayer AG and is currently in Phase 2 clinical development.
Asoprisnil is being developed by Bayer AG, a multinational pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY.
Asoprisnil is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. It is being studied for the treatment of menorrhagia.
Asoprisnil has been studied in a Phase 2 clinical trial with the identifier NCT00288691, titled 'Menorrhagia Study in Women With Treatment-resistant Menorrhagia'. This trial was completed and enrolled 26 female participants aged 30 years and older.
No alternative names for Asoprisnil have been reported. It is referred to solely by its generic name, Asoprisnil, in clinical and research contexts.